An empirical Bayes model for gene expression and methylation profiles in antiestrogen resistant breast cancer

BackgroundThe nuclear transcription factor estrogen receptor alpha (ER-alpha) is the target of several antiestrogen therapeutic agents for breast cancer. However, many ER-alpha positive patients do not respond to these treatments from the beginning, or stop responding after being treated for a period of time. Because of the association of gene transcription alteration and drug resistance and the emerging evidence on the role of DNA methylation on transcription regulation, understanding of these relationships can facilitate development of approaches to re-sensitize breast cancer cells to treatment by restoring DNA methylation patterns.MethodsWe constructed a hierarchical empirical Bayes model to investigate the simultaneous change of gene expression and promoter DNA methylation profiles among wild type (WT) and OHT/ICI resistant MCF7 breast cancer cell lines.ResultsWe found that compared with the WT cell lines, almost all of the genes in OHT or ICI resistant cell lines either do not show methylation change or hypomethylated. Moreover, the correlations between gene expression and methylation are quite heterogeneous across genes, suggesting the involvement of other factors in regulating transcription. Analysis of our results in combination with H3K4me2 data on OHT resistant cell lines suggests a clear interplay between DNA methylation and H3K4me2 in the regulation of gene expression. For hypomethylated genes with alteration of gene expression, most (~80%) are up-regulated, consistent with current view on the relationship between promoter methylation and gene expression.ConclusionsWe developed an empirical Bayes model to study the association between DNA methylation in the promoter region and gene expression. Our approach generates both global (across all genes) and local (individual gene) views of the interplay. It provides important insight on future effort to develop therapeutic agent to re-sensitize breast cancer cells to treatment.

[1]  D. Reinberg,et al.  Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. , 2001, Genes & development.

[2]  A. F. Smith.  A General Bayesian Linear Model , 1973 .

[3]  A. Fabiato,et al.  Anonymity of reviewers , 1994 .

[4]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[5]  S. Baylin,et al.  Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. , 1994, Cancer research.

[6]  Bing Li,et al.  The Role of Chromatin during Transcription , 2007, Cell.

[7]  J. Herman,et al.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.

[8]  S. Iguchi-Ariga,et al.  CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. , 1989, Genes & development.

[9]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[10]  D. Gianola,et al.  Bayesian analysis of mixed linear models via Gibbs sampling with an application to litter size in Iberian pigs , 1994, Genetics Selection Evolution.

[11]  Deepayan Sarkar,et al.  Detecting differential gene expression with a semiparametric hierarchical mixture method. , 2004, Biostatistics.

[12]  C. Allis,et al.  Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Min Gyu Lee,et al.  Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination , 2007, Science.

[14]  T. Clouaire,et al.  Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin? , 2008, Cellular and Molecular Life Sciences.

[15]  F. Watt,et al.  DNA methylation and specific protein-DNA interactions. , 1990, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[16]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[17]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[18]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[19]  H. Cedar,et al.  Linking DNA methylation and histone modification: patterns and paradigms , 2009, Nature Reviews Genetics.

[20]  Li Yu,et al.  [DNA methylation and cancer]. , 2005, Zhonghua nei ke za zhi.

[21]  Susan J. Clark,et al.  Breast cancer epigenetics: normal human mammary epithelial cells as a model system , 2008, Journal of Molecular Medicine.

[22]  Hongkai Ji,et al.  Analyzing 'omics data using hierarchical models , 2010, Nature Biotechnology.

[23]  D. Rubin,et al.  Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper , 1977 .

[24]  C. Ponting,et al.  Regulation of chromatin structure by site-specific histone H3 methyltransferases , 2000, Nature.

[25]  G. Coetzee,et al.  5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. , 1990, Science.

[26]  K. Nephew,et al.  Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. , 2009, BMC medical genomics.

[27]  Richard A Young,et al.  Chromatin immunoprecipitation and microarray-based analysis of protein location , 2006, Nature Protocols.

[28]  J. Herman,et al.  Hypermethylation of tumor suppressor genes in cancer. , 1999, Seminars in cancer biology.

[29]  G. McLachlan,et al.  The EM algorithm and extensions , 1996 .

[30]  Anthony Howell,et al.  Clinical development of fulvestrant ("Faslodex"). , 2005, Cancer treatment reviews.

[31]  Lang Li,et al.  Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. , 2006, Cancer research.

[32]  Wenxuan Zhong,et al.  Statistical assessment of the global regulatory role of histone acetylation in Saccharomyces cerevisiae , 2006, Genome Biology.

[33]  Weixing Feng,et al.  A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology , 2008, BMC Genomics.